Last reviewed · How we verify
Boostrix IPV infant whole Pertussis
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliomyelitis.
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliomyelitis. Used for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.
At a glance
| Generic name | Boostrix IPV infant whole Pertussis |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Boostrix IPV is an inactivated vaccine containing antigens from Corynebacterium diphtheriae toxoid, Clostridium tetani toxoid, acellular Bordetella pertussis components, and inactivated poliovirus types 1, 2, and 3. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, conferring protective immunity against these four vaccine-preventable diseases.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Gambia Pertussis Study (GaPs) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: